According to AbbVie, Skyliezi’s approval marks the first IL-23-specific inhibitor approved for both ulcerative colitis and Crohn’s disease, diseases of similar severity.
FDA approves AbbVie’s Skylie for treatment of adults with moderately to severely active ulcerative colitis
Leave a Comment
